Cefazolin vs cloxacillin in MSSA endocarditis: too good to be true?
Main Author: | David Tijmen Paulus Buis |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-05-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971224000493 |
Similar Items
-
Cefazolin versus cloxacillin in methicillin-susceptible Staphylococcus aureus endocarditis: Too good to be true? Authors’ reply
by: Laura Herrera-Hidalgo, et al.
Published: (2024-05-01) -
Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort
by: Laura Herrera-Hidalgo, et al.
Published: (2023-12-01) -
Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT
by: Laura Herrera-Hidalgo, et al.
Published: (2022-03-01) -
Continued in vitro cefazolin susceptibility in methicillin-susceptible Staphylococcus aureus
by: Benjamin H. Gern, et al.
Published: (2018-02-01) -
SYNTHESIS AND PHYSICOCHEMICAL STUDY OF THE CERIUM AND CEFAZOLIN METAL COMPLEX
by: T.V. Kryukov, et al.
Published: (2021-12-01)